| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -92,295 | -64,403 |
| Stock-based compensation expense | 11,266 | 7,806 |
| Depreciation | 3,011 | 2,079 |
| Amortization of premiums and discounts on marketable securities | 2,443 | 1,789 |
| Loss on disposal of fixed assets | -79 | -79 |
| Non-cash lease expense | 3,609 | 2,376 |
| Accounts receivable | 1,682 | 170 |
| Related party collaboration receivable | 175 | 175 |
| Prepaid expenses and other current assets | -1,327 | 1,826 |
| Accounts payable | -1,880 | -2,192 |
| Accrued expenses | 685 | -2,146 |
| Operating lease liabilities | -5,358 | -3,522 |
| Deferred revenue | -18,348 | -7,273 |
| Net cash used in operating activities | -102,204 | -71,156 |
| Purchases of property and equipment | 1,970 | 1,763 |
| Purchases of marketable securities | 121,426 | 114,790 |
| Proceeds from sales and maturities of marketable securities | 201,418 | 159,687 |
| Net cash provided by (used in) investing activities | 78,022 | 43,134 |
| Proceeds from the exercise of stock options | 246 | 161 |
| Proceeds from the purchase of common stock under espp | 434 | 434 |
| Net cash provided by financing activities | 680 | 595 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -23,502 | -27,427 |
| Cash and cash equivalents at beginning of period | 74,241 | - |
| Cash and cash equivalents at end of period | 50,739 | - |
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)